These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29296749)

  • 41. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
    Gao C; Leyton JV; Schimmer AD; Minden M; Reilly RM
    Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
    Capala ME; Vellenga E; Schuringa JJ
    PLoS One; 2014; 9(10):e111568. PubMed ID: 25360637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
    Li B; Zhao W; Zhang X; Wang J; Luo X; Baker SD; Jordan CT; Dong Y
    Bioorg Med Chem; 2016 Nov; 24(22):5855-5860. PubMed ID: 27687970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Patnaik MM; Mughal TI; Brooks C; Lindsay R; Pemmaraju N
    Leuk Lymphoma; 2021 Nov; 62(11):2568-2586. PubMed ID: 33999767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced functional response to CXCL12/SDF-1 through retroviral overexpression of CXCR4 on M07e cells: implications for hematopoietic stem cell transplantation.
    Porecha NK; English K; Hangoc G; Broxmeyer HE; Christopherson KW
    Stem Cells Dev; 2006 Jun; 15(3):325-33. PubMed ID: 16846371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progenitor egress from the bone marrow after allergen challenge: role of stromal cell-derived factor 1alpha and eotaxin.
    Dorman SC; Babirad I; Post J; Watson RM; Foley R; Jones GL; O'Byrne PM; Sehmi R
    J Allergy Clin Immunol; 2005 Mar; 115(3):501-7. PubMed ID: 15753896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma?
    Hira VVV; Van Noorden CJF; Molenaar RJ
    Biology (Basel); 2020 Feb; 9(2):. PubMed ID: 32079173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease.
    Chen W; Li M; Li Z; Yan Z; Cheng H; Pan B; Cao J; Chen C; Zeng L; Xu K
    Immunol Lett; 2012 Apr; 143(2):161-9. PubMed ID: 22342854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues.
    Huang S; Chen Z; Yu JF; Young D; Bashey A; Ho AD; Law P
    Stem Cells; 1999; 17(5):265-72. PubMed ID: 10527461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.
    Testa U; Pelosi E; Frankel A
    Biomark Res; 2014 Feb; 2(1):4. PubMed ID: 24513123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Datasets of a novel bivalent single chain antibody constructed by overlapping oligonucleotide annealing method targeting human CD123.
    Moradi-Kalbolandi S; Habibi-Anbouhi M; Golkar M; Behdani M; Rezaei G; Ghazizadeh L; Abolhassani M; Shokrgozar MA
    Data Brief; 2016 Sep; 8():1137-43. PubMed ID: 27536714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.
    Broughton SE; Hercus TR; Nero TL; Kan WL; Barry EF; Dottore M; Cheung Tung Shing KS; Morton CJ; Dhagat U; Hardy MP; Wilson NJ; Downton MT; Schieber C; Hughes TP; Lopez AF; Parker MW
    Nat Commun; 2018 Jan; 9(1):386. PubMed ID: 29374162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
    Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
    Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Signaling pathways governing the behaviors of leukemia stem cells.
    Azizidoost S; Nasrolahi A; Sheykhi-Sabzehpoush M; Anbiyaiee A; Khoshnam SE; Farzaneh M; Uddin S
    Genes Dis; 2024 Mar; 11(2):830-846. PubMed ID: 37692500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers as targets for CAR-T/NK cell therapy in AML.
    Shao R; Li Z; Xin H; Jiang S; Zhu Y; Liu J; Huang R; Xu K; Shi X
    Biomark Res; 2023 Jun; 11(1):65. PubMed ID: 37330575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
    Pelosi E; Castelli G; Testa U
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MARCH3 negatively regulates IL-3-triggered inflammatory response by mediating K48-linked polyubiquitination and degradation of IL-3Rα.
    Feng L; Li C; Zeng LW; Gao D; Sun YH; Zhong L; Lin H; Shu HB; Li S
    Signal Transduct Target Ther; 2022 Jan; 7(1):21. PubMed ID: 35075102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.